Phillips-Medisize, a Molex company, has built on a scalable technology that benefits pharmaceutical clients, and their providers and patients; it has released its third-generation connected health platform, which builds on the success of the company’s first offering, including the first FDA-approved combination product for medication adherence, and incorporates more than a decade of experience in developing connected health solutions.
Using connectivity in drug delivery devices such as injectors and inhalers, helps pharmaceutical companies, healthcare professionals and patients improve the process of taking medication. In addition to medication tracking, these systems support patients through reminders, incentives and peer communities so as to improve disease management, medication adherence and, ideally, outcomes.
Integration of information
Phillips-Medisize teamed with industry-leading healthcare IT providers to develop a platform that addresses the key challenges faced by the industry. The cloud-based third-generation connected health platform is a secure, reliable and scalable medical device data system. Using an industry-leading health integration engine combined with a rich analytics tool, it can integrate patient data with electronic medical records and other data from pharmacy and IoT devices, allowing customers to conduct insightful analysis focused on improving medication adherence.
– Bill Welch, Phillips-Medisize
"Phillips-Medisize is a leader in connected health systems for medicine that is currently on the market, supporting patients daily across the globe. This new, advanced connected health platform builds on our deep knowledge and experience," says Bill Welch, the chief technology officer for Phillips-Medisize. "For us, connected health is a strategy for better serving our customers and their patients, not a buzzword. We are unmatched in the industry with our global innovation, development and manufacturing capabilities to create end-to-end systems."
As connected health systems begin to demonstrate incremental improvements in adherence and patient outcomes, Phillips-Medisize expects the market to grow. The thirdgeneration platform further demonstrates the company’s commitment to meeting industry, provider and patient needs by building technology that is sensible, scalable and cost-effective.
The connected health solutions are driven by the companies connected health team and its global front-end-innovation team, which has expanded because of increased demand for device innovation and connected health services. Industry experts from leading consulting, medical technology and biopharma organisations have recently joined Phillips- Medisize’s connected health leadership team; together, they bring more than 80 years’ experience across all facets of connected health, from deep electronics and communications technology, to the impact of digitalisation for our customers’ global sales and marketing plans. The front-end-innovation team works with clients to develop differentiated and drugspecific strategies to better define clients’ connected health value propositions and enhance return on investment.
